Buy price
334.72
334.72
334.54
119.33 B
Information regarding past performance is not a reliable indicator of future performance.
The company’s stock has under-performed the broader market so far in 2024, while the company managed to beat EPS consensus estimates during the last quarter results. The company's pipeline seems to be promising and the company expects positive results from its candidates this year. Moreover, the FDA approval for Parsabiv which is a drug for hemodialysis is actually the first new treatment in more than 10 years. Going forward, strong competition and pipeline setbacks remain the company’s most significant headwinds.
Create an account and complete a quick verification.
Add money to your wallet via card, bank transfer, or crypto.
Choose AMGN, set the amount, and click buy or sell — that’s it!
Amgen
AMGN
334.63
-0.62%
FAQ